What Does an Alzheimer's Drug Relaunch Mean For A Cure? | Brain Talks | Being Patient
Last week, Biogen announced that its Alzheimer's drug aducanumab was effective in combating Alzheimer's disease after all, and that it would be reviving a trial cancelled earlier this year. However, questions still remain about what's next for patients and doctors as the drug moves toward FDA approval. Dr. Sharon Cohen, Medical Director and Principal Investigator at the Toronto Memory Program, shares her views on Biogen's revived trial and the potential behind aducanumab. Our mission is to give people impacted by dementia a better resource and connection to experts at the forefront of research. Our founder Deborah Kan funded Being Patient solely with her own savings to understand if people would value such a resource. Our audience has grown so rapidly, we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs. We employ a team of journalists to give you the best possible information on dementia and brain health without bias. To catch our Being Patient Perspectives Talks live, join our Facebook page: / beingpatientalzheimers For the latest news on dementia research and lifestyle tips, visit our site: https://www.beingpatient.com/
